Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

genetically modified interleukin-12 transgene-encoding Bifidobacterium longum

A live, genetically modified probiotic bacteria Bifidobacterium longum (B. longum) engineered to deliver genetic material encoding the human pro-inflammatory transgene interleukin-12 (IL-12), with potential immunoactivating activity. Upon administration of genetically modified IL-12 transgene-encoding B. longum, the bacteria selectively colonize hypoxic tumor tissues and deliver plasmid DNA encoding the IL-12 transgene within the tumor microenvironment (TME). IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Bifidobacterium longum encoding IL-12
genetically modified IL-12 transgene-encoding Bifidobacterium longum
Code name:bacTRL-IL-12
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search